Currently Recruiting

9 drug trials actively seeking PKD patients. Links go directly to ClinicalTrials.gov enrollment pages.

How to enroll in a clinical trial

Click the "View on ClinicalTrials.gov" link for any trial below to see eligibility criteria, locations, and contact information. Always discuss participation with your nephrologist first.

Drug Trials Enrolling Patients (9)

Click "View on ClinicalTrials.gov" for eligibility criteria, locations, and contact information

ABBV-CLS-628 Phase 2

Undisclosed mechanism; IV infusion every 4 weeks for 92 weeks

Calico Life Sciences / AbbVie ANCHOR 240 participants Est. completion: 2027-12
AZD1613 Phase 1

PAPPA-1 inhibitor

AstraZeneca PIONEER-PKD 40 participants Est. completion: 2027-01
Dapagliflozin Phase 3

SGLT2 inhibitor

University of Cologne STOP-PKD 420 participants Est. completion: 2029
Empagliflozin Phase 2

SGLT2 inhibitor

Multiple Sponsors EMPA-PKD / SIDIA / Colorado Feasibility 134 participants Est. completion: 2027-05
JMKX003142 Phase 2

Oral small molecule

Jemincare Phase 2 ADPKD 135 participants Est. completion: 2027
Metformin Phase 3

AMPK activator

University of Queensland IMPEDE-PKD 1174 participants Est. completion: 2027
PYC-003 Phase 1

Peptide-PMO conjugate antisense therapy targeting PKD1 mutations, delivered IV

PYC Therapeutics First-in-Human PKD1 116 participants Est. completion: 2027
Tirzepatide Phase 2

GLP-1/GIP dual receptor agonist

University of Colorado Denver Tirzepatide in Overweight ADPKD 126 participants Est. completion: 2027
VX-407 Phase 2

Oral small molecule

Vertex Pharmaceuticals AGLOW 24 participants Est. completion: 2027

Disclaimer: Enrollment links direct to ClinicalTrials.gov, where you can find full eligibility criteria and site locations. Meeting eligibility criteria does not guarantee enrollment. Always consult your nephrologist before participating in a clinical trial.

Stay Updated on PKD Research

Get notified when new drugs enter clinical trials, trial results are published, or approved treatments change.

No spam. Unsubscribe anytime.